Consequently, targeting one of the main intracellular defence mechanisms to counteract oxidative stress—the Keap1/Nrf2 signalling pathway—could be a viable therapeutic strategy for ALS/FTD. The gene discussed is KEAP1; the disease is frontotemporal dementia.